Random Analytica: AstraZeneca COVID-19 vaccine and cases of Thrombosis with thrombocytopenia syndrome (TTS)
by Shane Granger
AstraZeneca is in the news this week after the Therapeutic Goods Administration (TGA) reported the death of a 52-woman from New South Wales from thrombosis with thrombocytopenia syndrome (TTS). This is the second fatality linked to the AstraZeneca vaccination roll-out following the death of a 48-year old female in April. As tragic as the deaths are there have been almost 3.3-million doses of AstraZeneca administered (to the 6th June 2021) with just 48-cases of TTS being reported to date. For context it looks like you could expect an adverse reaction resulting in death in 1 in every 1.65-million doses. According to Ian Mackay from Virology Down Under “It’s a real number. A real risk. But a very rare one”.
[…] No data was available in this report on AstraZeneca vaccines administered (in the previous week 3.3-million doses were confirmed). At the same time the Australian Technical Advisory Group on Immunisation (ATAGI) recommended the age to receive a dose be increased from 50 to 60. To date there have been two TTS deaths linked to the AstraZeneca vaccine. […]
[…] The case which should be removed from the above chart is in the 50s age cohort. As per last week no AstraZeneca vaccination numbers were provided in the report although the number must be close to 4-million. On 17 June 2021, the Australian Technical Advisory Group on Immunisation (ATAGI) recommended that Pfizer’s Comirnaty vaccine be preferred over the AstraZeneca vaccine for those aged 16–60 years old. To date there have been two TTS deaths linked to the AstraZeneca vaccine. […]
[…] To date there have been approximately 4.6-million doses of AstraZeneca administered to 30 June (h/t CovidBaseAU) and two confirmed TTS deaths linked to the AstraZeneca vaccine. […]